ARTICLE | Clinical News
CM-3: Phase I started
September 27, 2010 7:00 AM UTC
Biocompatibles began a double-blind, placebo-controlled, 4-way crossover, German Phase I trial to evaluate single-ascending doses of subcutaneous CM-3 in up to 16 patients. AstraZeneca plc (LSE:AZN; ...